Why carry out this study?

There is a paucity of real-world outcomes data on the utility of mold-active triazoles (MATs) in the management of invasive fungal infections (IFIs).

The purpose of this registry-based observational study was to examine patient characteristics and therapy patterns of a ‘real-world’ patient population receiving a MAT for IFIs to better understand the use of these agents in current clinical practice.

What was learned from the study?

This study characterized and described the demographic characteristics of the at-risk population of patients on MAT therapy for the management of IFIs, thereby adding to the evolving data for this significant health problem.

MATs were associated with favorable clinical, mycologic, and radiologic responses in approximately half of patients who were assessed, and breakthrough IFIs were rare in those receiving MAT prophylaxis. However, the choice of MAT and use of therapeutic drug monitoring are physician- and center-dependent and may not be well standardized.

The findings from this study support targeted changes in therapy to align with guideline recommendations, which may result in positive outcomes when managing patients with, and at risk for, IFIs.